Health Canada has granted authorisation to in-vitro medical diagnostics provider bioLytical Laboratories for its INSTI multiplex HIV-1/2 Syphilis Antibody Test.

Authorised for professional point-of-care use, the test can identify both HIV-1/2 and syphilis antibodies from one sample, gathered using a simple fingerprick method.

The test is claimed to provide precise results in less than one minute.

bioLytical is also working on a self-test version to help Canadians of all demographics access regular and early testing for both infections.

The INSTI test enables healthcare professionals to test in different environments, offering flexible options for individuals who face barriers to accessing healthcare.

As part of Health Canada’s review and subsequent authorisation, the two-year Point of Care Tests for Syphilis and HIV (PoSH) Study was conducted between August 2020 and February 2022.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Led by researchers at the University of Alberta and St Michael’s hospital, the trial demonstrated the significance of regular and frequent testing to help connect patients to care.

The majority (87.4%) of participants were treated immediately following point-of-care results, while the rest received treatment within a median of four days.

bioLytical CEO Rob Mackie said: “I am proud to lead a team of hardworking and innovative individuals who consistently push the boundaries of what is possible.

“Our continued dedication to excellence allowed us to achieve this remarkable milestone that will help Canadians across all demographics access early testing in various settings.”        

With a 166% nationwide increase between 2017 and 2021, Canada is presently experiencing unprecedented syphilis infection rates, noted the company.

Last April, Health Canada authorised the company’s iStatis Covid-19 Antigen Home Test, which can be performed at home with easy-to-understand results.